Earlier this month, a team from the Henry J. Kaiser Family Health Foundation traveled to Puerto Rico as well as the US Virgin Islands to assess the recovery of the healthcare system 6 months following Hurricane Maria. What they found is a very mixed situation, with some areas faring better than others, but with much more work remaining before the islands can restore to a state of normalcy. Compounding the problem, the next hurricane season is approaching while the area has not yet recovered from the first one.
Earlier this month, a team from the Henry J. Kaiser Family Health Foundation traveled to Puerto Rico as well as the US Virgin Islands to assess the recovery of the healthcare system 6 months following Hurricane Maria.
What they found, after interviewing more than 30 residents, business owners, healthcare providers, and territory officials, as well as phone interviews with federal officials and other organizations, is a very mixed situation, with some areas faring better than others, but with much more work remaining before the islands can restore to a state of normalcy.
Compounding the problem, the next hurricane season is approaching while the area has not yet recovered from the first one.
“Healthcare is really the foundation for the sustained economic recovery on the islands,” said Barbara Lyons, senior vice president, Henry J. Kaiser Family Foundation.
She said everything else—tourism, job creation, and other factors—all hinges on having a reliable healthcare system in place. It will require investment, particularly in the form of Medicaid dollars, she said.
Samantha Artiga, the foundation’s disparities policy project director, said overall, progress has continued, but issues delivering healthcare on Puerto Rico and the US Virgin Islands remain:
In Puerto Rico:
Rafael Rodríguez-Mercado, MD, secretary of health for Puerto Rico, compared Hurricane Maria to going to bed on September 19, 2017, and “waking up in 1955” the next day. He credited nonprofits and nongovernmental organizations for preventing a more severe health crisis in remote areas.
In the US Virgin Islands:
In addition to the physical damage, Puerto Rico has major fiscal challenges.
Artiga said federal relief funding for Medicaid provides key support, but that relief funding does not address long-term underlying fiscal problems or disparity in federal match and cap on federal funds. In 2019 that relief funding will end, causing major issues.
Puerto Rico faces the added challenge of implementing major delivery system reform and achieving savings specified by the Fiscal Oversight Board. The US Virgin Islands is also engaged in broader delivery system reform efforts, she said.
The board is demanding that Puerto Rico save $100 million a year for each of the next 5 years. Rodríguez-Mercado said Puerto Rico may reach a point where “we may save money but we are not going to have health providers to offer services to the people of Puerto Rico."
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More